Mauldin, Ileana S.
Wages, Nolan A.
Stowman, Anne M.
Wang, Ena
Olson, Walter C.
Deacon, Donna H.
Smith, Kelly T.
Galeassi, Nadedja
Teague, Jessica E.
Smolkin, Mark E.
ChianeseāBullock, Kimberly A.
Clark, Rachael A.
Petroni, Gina R.
Marincola, Francesco M.
Mullins, David W.
Slingluff, Craig L. Jr.
Funding for this research was provided by:
University of Virginia Cancer Center Support Grant (NIH/NCI P30 CA44579)
Melanoma Research Alliance Young Investigator Award
UVA Cancer Training Grant (T32 CA009109)
National Cancer Institute (NIH/NCI grant K25 CA181638)
Article History
Received: 21 March 2016
Accepted: 2 August 2016
First Online: 13 August 2016
Compliance with ethical standards
:
: Craig Slingluff is an inventor of several peptides included in the vaccine that was administered during the clinical trials studied within this paper. The University of Virginia Licensing and Ventures Group holds the patents for those peptides, which have been licensed through the Ludwig Institute for Cancer Research to Glaxo Smith Kline. He also has relationships with several commercial interests related to this work, including Immatics (member, Scientific Advisory Board), Polynoma (principal investigator for MAVIS cancer vaccine trial), Glaxo Smith Kline (recipient of grant support for a clinical trial), but funds from those relationships go to the University of Virginia, not to Dr. Slingluff personally. The remaining authors have nothing to disclose or competing interests in association with this study.